PAG
MRTX

Private Advisor Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Private Advisor Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-550
Closed -$63K – 3623
2020
Q2 		$63K Buy
+550
New +$53.3K ﹤0.01% 1974

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Private Advisor Group's MRTX Position: Q3 2020 in Review

Private Advisor Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2020, closing a stake of 550 shares — an estimated $63K sold.

Private Advisor Group first reported a position in MRTX in Q2 2020 and held it in 1 quarter. The position peaked at $63K in Q2 2020. 225 funds tracked by Wall St. Rank hold MRTX as of Q3 2020.

  • Private Advisor Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 550 Mirati Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $63K.
  • Private Advisor Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's Mirati Therapeutics, Inc. Common Stock position peaked at $63K in Q2 2020.
  • 225 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.